DE2605656A1 - Pharmazeutische zubereitungen in tablettenform - Google Patents
Pharmazeutische zubereitungen in tablettenformInfo
- Publication number
- DE2605656A1 DE2605656A1 DE19762605656 DE2605656A DE2605656A1 DE 2605656 A1 DE2605656 A1 DE 2605656A1 DE 19762605656 DE19762605656 DE 19762605656 DE 2605656 A DE2605656 A DE 2605656A DE 2605656 A1 DE2605656 A1 DE 2605656A1
- Authority
- DE
- Germany
- Prior art keywords
- tablet
- tablet according
- sulfonamide
- particle size
- disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 42
- 150000003456 sulfonamides Chemical class 0.000 claims description 41
- 239000002245 particle Substances 0.000 claims description 26
- 230000008961 swelling Effects 0.000 claims description 12
- 239000003979 granulating agent Substances 0.000 claims description 8
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 8
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 5
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims description 4
- 229960002135 sulfadimidine Drugs 0.000 claims description 3
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004257 sulfaguanidine Drugs 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- -1 phthalylsulfathazole Chemical compound 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229920003110 Primojel Polymers 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 4
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 3
- 229960002229 sulfametoxydiazine Drugs 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- PQWVFANWIMLZPD-UHFFFAOYSA-N 1-aminocyclohexa-2,4-diene-1-sulfonamide Chemical compound NS(=O)(=O)C1(N)CC=CC=C1 PQWVFANWIMLZPD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB6174/75A GB1533243A (en) | 1975-02-13 | 1975-02-13 | Tablet formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2605656A1 true DE2605656A1 (de) | 1976-08-26 |
Family
ID=9809772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762605656 Withdrawn DE2605656A1 (de) | 1975-02-13 | 1976-02-12 | Pharmazeutische zubereitungen in tablettenform |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS51106711A (https=) |
| BE (1) | BE838507A (https=) |
| CA (1) | CA1052267A (https=) |
| DE (1) | DE2605656A1 (https=) |
| DK (1) | DK57376A (https=) |
| FI (1) | FI760340A7 (https=) |
| FR (1) | FR2300550A1 (https=) |
| GB (1) | GB1533243A (https=) |
| HU (1) | HU171201B (https=) |
| IE (1) | IE42952B1 (https=) |
| IL (1) | IL49024A (https=) |
| NL (1) | NL7601423A (https=) |
| SE (1) | SE7601564L (https=) |
| ZA (1) | ZA76829B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| ZA822995B (en) * | 1981-05-21 | 1983-12-28 | Wyeth John & Brother Ltd | Slow release pharmaceutical composition |
| US5629016A (en) * | 1991-01-30 | 1997-05-13 | Glaxo Wellcome Inc. | Water-dispersible tablets |
| MY110880A (en) * | 1991-01-30 | 1999-06-30 | The Wellcome Foundation Ltd | Water-dispersible tablets |
| US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
| US20040109889A1 (en) | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1460302A (en) * | 1973-05-23 | 1977-01-06 | Wellcome Found | Tablet formulation |
| GB1499672A (en) * | 1974-02-14 | 1978-02-01 | Wellcome Found | Tablet formulation |
-
1975
- 1975-02-13 GB GB6174/75A patent/GB1533243A/en not_active Expired
-
1976
- 1976-02-12 IE IE272/76A patent/IE42952B1/en unknown
- 1976-02-12 JP JP51014332A patent/JPS51106711A/ja active Pending
- 1976-02-12 FI FI760340A patent/FI760340A7/fi not_active Application Discontinuation
- 1976-02-12 HU HU76WE00000534A patent/HU171201B/hu unknown
- 1976-02-12 BE BE164281A patent/BE838507A/xx unknown
- 1976-02-12 DK DK57376*#A patent/DK57376A/da unknown
- 1976-02-12 IL IL7649024A patent/IL49024A/xx unknown
- 1976-02-12 FR FR7603829A patent/FR2300550A1/fr active Granted
- 1976-02-12 NL NL7601423A patent/NL7601423A/xx not_active Application Discontinuation
- 1976-02-12 CA CA245,882A patent/CA1052267A/en not_active Expired
- 1976-02-12 SE SE7601564A patent/SE7601564L/xx unknown
- 1976-02-12 DE DE19762605656 patent/DE2605656A1/de not_active Withdrawn
- 1976-02-12 ZA ZA760829A patent/ZA76829B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK57376A (da) | 1976-08-14 |
| CA1052267A (en) | 1979-04-10 |
| FR2300550B1 (https=) | 1979-09-21 |
| IE42952B1 (en) | 1980-11-19 |
| FI760340A7 (https=) | 1976-08-14 |
| ZA76829B (en) | 1977-09-28 |
| BE838507A (fr) | 1976-08-12 |
| IL49024A0 (en) | 1976-04-30 |
| FR2300550A1 (fr) | 1976-09-10 |
| IL49024A (en) | 1979-03-12 |
| HU171201B (hu) | 1977-11-28 |
| AU1110876A (en) | 1977-08-18 |
| SE7601564L (sv) | 1976-08-16 |
| NL7601423A (nl) | 1976-08-17 |
| GB1533243A (en) | 1978-11-22 |
| IE42952L (en) | 1976-08-13 |
| JPS51106711A (https=) | 1976-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69311395T2 (de) | Sphäroidische Arzneimittelformulierung | |
| DE69732312T2 (de) | Schnellzerfallendes Granulate von einem synthetischen Süssstoff enthaltend Kieselsäure und/oder Siliciumdioxid | |
| DE3887179T2 (de) | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. | |
| DE3877764T2 (de) | Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren. | |
| EP0108898B1 (de) | Neue orale Mopidamolformen | |
| DE68916983T2 (de) | Verfahren zur Herstellung eines pharmazeutischen Granulats. | |
| DE69400356T2 (de) | Quervernetzte amylose als bindemittel/sprengmittel fuer tabletten | |
| DE3228999C2 (de) | Pharmazeutische Zusammensetzungen mit verzögerter Wirkstofffreigabe | |
| DE2200778B2 (de) | Verwendung von hochmolekularem, unlöslichem, quervernetztem Polyvinylpyrrolidon als Sprengmittel in festen Arzneiformen | |
| DE2706660A1 (de) | Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung | |
| DE1492253A1 (de) | Verfahren zur Herstellung von Tabletten mit protrahierter Wirkung | |
| DE60129515T2 (de) | Basismaterial zur trockenen Direkttablettierung enthaltend niedrig substituierte Hydroxypropylcellulose | |
| DE2605656A1 (de) | Pharmazeutische zubereitungen in tablettenform | |
| DE3150557C2 (https=) | ||
| DE2506099C2 (de) | Sulfonamid und Trimethoprim enthaltende Tablette | |
| DE3873011T2 (de) | Pharmazeutische zusammensetzung, enthaltend piperidinalkanolderivate. | |
| DE1925919C3 (de) | Tablette für die gleichmäßige Freisetzung eines Arzneimittels | |
| DE2050701C3 (de) | Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen | |
| DE69330392T2 (de) | Cytarabine Ocfosfate enthaltende harte Kapsel | |
| DE68907609T2 (de) | Arzneimittelzusammensetzung. | |
| DE1617638A1 (de) | Tablettenbindemittel | |
| DE1931910A1 (de) | Verfahren zur Herstellung von festen Arzneizubereitungen mit gesteuerter Resorption | |
| DE3942131C2 (de) | Pharmazeutisches Trimebutin-haltiges Präparat mit verlängerter Wirkstoff-Freisetzung und Verfahren zur Herstellung | |
| DE2148391A1 (de) | Arzneimittel mit verlängerter Wirk stoffabgabe | |
| DE69002477T2 (de) | Salsalat-Tablette. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |